On 18 July 2018, MPs have voted for the UK to start negotiation to remain part of the European Medicines Agency following Brexit. According to Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry, and Steve Bates, chief executive of the BioIndustry Association, “Parliament has sent a clear message that patients and public health should be a top priority for the Government in these negotiations”.
It may be that in the near future, an agreement will be reached whereby the UK-based Marketing Authorisation holders will only have to take minimum steps, if any, to keep their products on the single market. However, please do note that this is not an official part of the Brexit process and may still be changed. For more information on how to prepare for Brexit, please refer to this section – https://mapbiopharma.com/europe/legal/brexit-in-market-access/.